

Press Release

CUP Contract Labs Grants Exclusive License to TRASIS for the Advanced RADIOSTER® Cassette for Automated Sterility Testing

Radeberg, Germany / Ans, Belgium, May 26th, 2025

CUP Contract Labs, a premier provider of pharmaceutical testing services, today announced an exclusive licensing agreement with TRASIS, a recognized innovator in nuclear medicine technologies, for its patented RADIOSTER® cassette. This agreement provides TRASIS with exclusive rights to develop, manufacture, market, and distribute the solution worldwide under the brand name **Sterinow®**, aimed at making this groundbreaking technology accessible to clients worldwide. To ensure a perfect alignment with both market needs and regulatory requirements, development and validation operations are carried out jointly by TRASIS and CUP Contract Labs - a powerful collaboration bringing together complementary expertise to deliver a robust and compliant solution. The **Sterinow®** cutting-edge cassette is specifically designed for automated sterility testing of radiopharmaceuticals using membrane filtration, enhancing the safety of these critical treatments. It allows safe, efficient, and operator-independent sample preparation, fully integrated into Trasiss' ecosystem of radiopharmaceutical production equipment.

By incorporating **Sterinow®** asset into its state-of-the-art portfolio solutions, TRASIS aims to transform the production processes for radiopharmaceuticals globally, setting new standards in the quality and safety of these manufacturing processes. This pioneering automation innovation streamlines and secures the critical sterility testing step in the production of radiopharmaceuticals, while fully aligning with the highest regulatory and quality standards, setting a new benchmark for the industry.

"We are excited to collaborate with TRASIS to make our innovative RADIOSTER® technology available to a global clientele through the **Sterinow®** automated solution which aligns with our goal of enhancing radiopharmaceutical safety and ensuring high-quality patient treatments," said Dirk Freitag-Stechl, Managing Director of CUP Contract Labs.

Gauthier Philippart, CEO of TRASIS, commented, "Integrating the **Sterinow®** automated solution into our portfolio enables us to offer more advanced, efficient solutions, significantly improving the sterility testing processes and meeting the stringent regulatory standards for pharmaceutical safety."

Notes to Editors

About TRASIS

TRASIS is a leader in the radiopharmaceutical sector, dedicated to the development and offering of comprehensive solutions for the production of radioactive drugs. Trasis's products, including synthesizers, quality control systems and associated consumables are essential in enhancing the safe and efficient production of radiopharmaceuticals globally.

Contact

Gauthier Philippart, CEO

TRASIS

Rue Gilles Magnée 90

BE-4430 Ans, Belgium

Tel +32-4-365 86 57 www.trasis.com

About CUP Contract Labs

Founded in 1991 and based in Radeberg, Germany, CUP Contract Labs specializes in chemical and microbiological GMP testing services, focusing particularly on radiopharmaceuticals. The company is renowned for its adherence to GMP and FDA standards, ensuring top-quality testing services.

Contact

Dr. Dirk Freitag-Stechl, M.B.A., Managing Director

CUP Laboratorien Dr. Freitag GmbH

Carl-Eschebach-Str. 7

01454 Radeberg, Germany

Tel +49 (0) 3528 22909-20

www.cup-contract-labs.com